The team, led by Marco Antonio Araújo da Rocha-Loures of the Clínica de Reumatismo in Maringá, Brazil, and supported by the Brazilian Society of Rheumatology, conducted an exhaustive search across eight major databases, including PubMed, EMBASE, Scopus, the Cochrane Library, Web of Science, SciELO, PEDro and LILACS, supplemented by gray literature sources. Their aim was to answer a deceptively simple question: in men with primary or secondary osteoporosis, which interventions actually reduce fracture risk and improve bone mineral density? The investigators followed the PRISMA reporting framework and used the Cochrane Handbook for systematic reviews, version 6.5, as their methodological backbone. Statistical analyses were performed in RStudio version 4.3.3, and the risk of bias in each included trial was assessed with the Cochrane RoB 2 tool, the current standard for evaluating randomized studies.

After screening the literature, the reviewers settled on twelve randomized controlled trials. Ten of these tested pharmacological interventions, one examined a nutritional supplement, and one evaluated an exercise program. The pooled study populations had a mean age of 60.9 years, with a standard deviation of 5.2 years, and baseline disease severity that qualifies as established osteoporosis by any conventional definition: average T-scores of minus 2.9 at the lumbar spine and minus 2.7 at the femoral neck. A T-score expresses how many standard deviations a person’s bone density lies below the young adult mean, and values below minus 2.5 define osteoporosis under World Health Organization criteria. These were not marginal cases; these were men with substantially compromised skeletons.

The pharmacological findings centered on two drug classes that dominate osteoporosis therapy worldwide. Bisphosphonates—represented in the included trials by alendronate and risedronate—work by binding to bone mineral and poisoning the osteoclasts, the cells that resorb bone, thereby tipping the delicate balance of bone remodeling toward formation. The antiresorptive effect is well documented, and the trials reviewed here confirmed that both agents produce measurable gains in bone mineral density at the spine and hip in men. Teriparatide, the second major therapy evaluated, takes the opposite mechanistic approach. As a recombinant fragment of human parathyroid hormone, comprising the first 34 amino acids, it is administered by daily injection and acts as an anabolic agent, stimulating osteoblasts to build new bone rather than simply slowing its loss. The landmark trial by Orwoll and colleagues, included in this review, demonstrated significant bone density gains in osteoporotic men treated with teriparatide, and a combination study testing risedronate alongside teriparatide explored whether pairing an anabolic with an antiresorptive agent yields additive benefits.

Yet when the reviewers looked beyond bone density to the outcome that ultimately matters—fractures—the picture became decidedly less reassuring. The effects of pharmacological treatment on fracture risk were described as inconsistent across the included trials. This is not because the drugs have been proven ineffective at preventing fractures; it is because the trials in men were generally too small, too short, or too sparsely powered to detect fracture reduction with statistical confidence. Fractures are relatively rare events even in osteoporotic populations over the time frames typical of clinical trials, and demonstrating a meaningful reduction requires thousands of patient-years of follow-up. Almost all of the definitive fracture data for bisphosphonates and teriparatide come from trials conducted predominantly in postmenopausal women, and regulators and guideline writers have long extrapolated those results to men. The new review makes clear how much of the male-specific evidence base rests on that extrapolation rather than on direct demonstration.

The non-pharmacological arm of the review offered some of its most intriguing, if preliminary, findings. A single exercise-based trial examined resistance training in men with secondary osteoporosis following hemiplegia, using weight-training sessions lasting 60 to 90 minutes per day. That regimen was associated with improvements in bone mineral density, consistent with the mechanistic understanding that mechanical loading stimulates osteogenesis through skeletal strain detected by osteocytes, which in turn signal osteoblast recruitment. The Wolff’s law principle—that bone adapts to the loads placed upon it—has underpinned exercise recommendations for skeletal health for over a century, but robust randomized evidence in older men with established osteoporosis has been scarce. The second non-pharmacological trial tested L-carnitine, a compound involved in mitochondrial fatty acid transport that has been hypothesized to influence bone metabolism through effects on osteoblast activity, and reported bone density benefits as well. Both findings, the reviewers caution, are limited by methodological constraints in the underlying studies, and neither can be considered practice-changing on its own.

Risk of bias across the twelve trials varied considerably, a finding that colors every conclusion the review can offer. The RoB 2 assessment examines domains including the randomization process, deviations from intended interventions, missing outcome data, measurement of outcomes, and selective reporting. Trials of older drugs conducted decades ago often fall short of contemporary standards for blinding, allocation concealment, and pre-registered outcome definitions. When the reviewers weighted the totality of evidence, they concluded that pharmacological therapies do improve bone mineral density in older men, but that the evidence remains insufficient to demonstrate consistent fracture risk reduction, and that non-pharmacological interventions show potential benefits supported only by limited evidence.

The clinical implications of these gaps are considerable. Osteoporosis in men is widely acknowledged to be underdiagnosed and undertreated, and the consequences of that neglect are severe: men account for a substantial fraction of hip fractures, and men who sustain a hip fracture experience higher mortality than women with comparable injuries. Vertebral fractures in men frequently go unrecognized, and secondary causes—including hypogonadism, glucocorticoid use, alcohol excess, and malabsorption—are common yet often uninvestigated. Guidelines from bodies such as the Endocrine Society have recommended bisphosphonates as first-line therapy for men at high fracture risk, but those recommendations rest in large part on bone density surrogates and on fracture data imported from female populations. Surrogate endpoints like bone mineral density correlate with fracture risk, but the correlation is imperfect, and treatments can produce density gains without proportional fracture reduction, as has been demonstrated in other therapeutic contexts.

What the review ultimately argues for is a new generation of adequately powered randomized trials in men, designed with fractures as the primary endpoint rather than bone density. Such trials are expensive and logistically demanding, requiring large sample sizes and multi-year follow-up, but the reviewers contend that they are the only way to place male osteoporosis management on the same evidentiary footing as postmenopausal osteoporosis. They also call for better-designed studies of non-pharmacological approaches, noting that exercise interventions in particular could offer fractal benefits—improved balance, muscle strength, and fall prevention—that drugs cannot provide, and that falls are the proximate cause of the majority of fragility fractures in older adults. An intervention that reduces falls while modestly increasing bone density could, in principle, deliver a combined fracture-prevention effect larger than either mechanism alone.

For the millions of older men living with low bone mass worldwide, the practical takeaways from the review are nonetheless reasonably clear. The existing pharmacological arsenal—bisphosphonates and teriparatide foremost among them—does increase bone density in men, and no signal of unexpected harm emerged from the analyzed trials, making continued use consistent with current guidelines a defensible clinical stance. At the same time, men and their physicians should not assume that the fracture-prevention benefits observed in women have been proven directly in men, and the review’s authors hope their work will spur both researchers and funders to close a gap that has persisted for decades. Bone health in aging men, long a footnote in osteoporosis research, is finally receiving the systematic scrutiny it has long deserved—and the scrutiny reveals just how much work remains to be done.

The study published in the Archives of Osteoporosis emphasizes the importance of treatment frequency in managing osteoporosis effectively. Traditionally, teriparatide, a synthetic form of parathyroid hormone, has been administered daily. In their investigation, Tominaga et al. explored whether reducing the dosing frequency while maintaining therapeutic outcomes would be feasible. By adjusting the treatment regimen, clinicians may potentially enhance patient adherence, which is crucial for long-term management of osteoporotic conditions.

The research focused on a cohort of postmenopausal women diagnosed with osteoporosis. This demographic is most at risk for osteoporosis-related fractures, making it imperative to explore treatment methods that can enhance their quality of life. Preliminary findings indicated that those receiving a twice-weekly regimen exhibited improvements not just in bone density but also in overall fracture risk reduction. This is particularly encouraging, as non-compliance to daily medication regimens has frequently been cited as a significant barrier to effective osteoporosis treatment.

Furthermore, the study highlighted both the biochemical and clinical markers of bone health that were positively influenced by the reduced frequency of teriparatide administration. Notable is the increase in bone mineral density, a key indicator of bone health. The participants who adhered to this new dosing schedule demonstrated results comparable to those who had been on the conventional daily therapy. This breakthrough suggests that patients may experience similar benefits with fewer injections, ultimately enhancing their treatment experience.

Safety is often a paramount consideration in pharmacological treatment plans, especially in elderly populations who may have comorbidities and be on multiple medications. The research team meticulously monitored for any adverse effects associated with the twice-weekly administration of teriparatide. Initial results indicate a similar safety profile to that of daily administration, which would be critical in broadening the acceptance of this treatment protocol. Continued monitoring, however, is essential to understand the long-term impacts fully.

The implications of this study could extend beyond just the treatment of osteoporosis. With the ongoing evolution in the field of healthcare towards personalized medicine, findings like these pave the way for an adaptive approach to treatment. As evidence mounts regarding improved patient outcomes with modified dosing frequencies, guidelines might evolve to incorporate these findings, encouraging clinicians to tailor treatments based on individual patient needs and lifestyles.

Moreover, the economic aspect of osteoporosis treatments cannot be overlooked. The frequency of injections and overall healthcare costs associated with managing osteoporosis can place a significant burden on both healthcare systems and patients. By reducing the injection frequency, the financial implications of osteoporosis management could be substantially lowered, making treatment more accessible.

The researchers did not limit their analyses to solely clinical and biochemical data. They also incorporated patient-reported outcomes to capture the overall impact on quality of life. Perspectives from the participants shed light on the psychological and emotional facets of living with osteoporosis and undergoing treatment. This holistic view underscores the necessity of involving patients in their treatment plans and acknowledging their preferences and experiences, which can greatly influence adherence and outcomes.

Public response to the findings is likely to garner considerable interest, as patients seek more manageable solutions to their health challenges. This research may empower individuals with osteoporosis to advocate for their treatment preferences, leading to a more engaged patient population. As studies like this gain traction, there is potential for increased awareness of osteoporosis management techniques, emphasizing the importance of research-driven treatment.

Concerning practical implementation, healthcare providers may need to engage in further education regarding this novel regimen. As clinicians remain vigilant about emerging research, integrating new findings into practice will be essential. Medical professionals may need to recalibrate their approach to discussing treatment options with patients, highlighting the benefits of a more flexible administration schedule.

In summary, Tominaga et al.’s study on the clinical outcomes of twice-weekly teriparatide administration is a significant contribution to osteoporosis research. It opens the door to reimagining treatment paradigms and may ultimately shift existing protocols toward more patient-centered care models. As the healthcare landscape evolves, such breakthroughs remind us of the critical importance of evidence-based practice in fostering advancements in patient care.

Looking ahead, further investigations will be essential to validate these findings across diverse populations and settings. Long-term clinical trials will be required to assess the sustainability and efficacy of this treatment approach. The implications of this research, if affirmed by future studies, could indeed pave the way for changes in osteoporosis treatment guidelines and offer renewed hope to millions affected by this debilitating disease.

Ultimately, advances in osteoporosis treatment not only hold promise for individual patients but also herald a broader revolution in chronic disease management. As exciting new data emerges, the commitment to facilitating improved outcomes for patients will remain at the forefront of the healthcare agenda, ensuring that science continues to serve humanity’s needs.

Subject of Research: Osteoporosis treatment with teriparatide acetate

Article Title: Clinical outcomes of twice-weekly teriparatide acetate administration in osteoporosis

Article References: Tominaga, A., Maruki, H., Wada, K. et al. Clinical outcomes of twice-weekly teriparatide acetate administration in osteoporosis. Arch Osteoporos 20, 144 (2025). https://doi.org/10.1007/s11657-025-01622-4

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s11657-025-01622-4

Keywords: Osteoporosis, teriparatide acetate, twice-weekly administration, bone density, treatment compliance, health outcomes.